PPD's Beijing lab gets CAP accredition

27 April 2009

USA contract research firm PPD says its global central laboratory operations in Beijing, China, has earned accreditation by the College of  American Pathologists, making it the company's third central lab to meet  the highest standard of excellence in enhancing patient safety and  speeding drug development.

The CAP Laboratory Accreditation Program is an  internationally-recognized program using rigorous accreditation  standards to help laboratories advance the quality of laboratory  services to improve patient care. The program uses multi-disciplinary  teams of practicing lab professionals as inspectors who assess  management and operations of laboratories, extending beyond regulatory  requirements.

"Earning CAP accreditation at our Beijing partner lab validates our  commitment to deliver high-quality, reliable data to our clients in a  high-growth region for global clinical research," said Steve Lobel, vice  president of PPD's global central laboratory operations.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight